Share on StockTwits

Questcor Pharmaceuticals (NASDAQ:QCOR) Insider Michael H. Mulroy sold 10,000 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $87.99, for a total value of $879,900.00. Following the transaction, the insider now directly owns 77,063 shares in the company, valued at approximately $6,780,773. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Questcor Pharmaceuticals (NASDAQ:QCOR) traded up 0.11% on Wednesday, hitting $87.16. 1,436,218 shares of the company’s stock traded hands. Questcor Pharmaceuticals has a 1-year low of $33.00 and a 1-year high of $90.97. The stock has a 50-day moving average of $78.02 and a 200-day moving average of $65.65. The company has a market cap of $5.155 billion and a P/E ratio of 16.44. Questcor Pharmaceuticals also was the recipient of some unusual options trading activity on Wednesday. Stock investors purchased 11,206 put options on the company. This represents an increase of approximately 104% compared to the average daily volume of 5,484 put options.

Questcor Pharmaceuticals (NASDAQ:QCOR) last released its earnings data on Monday, April 28th. The company reported $1.40 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.61 by $0.21. The company had revenue of $227.10 million for the quarter, compared to the consensus estimate of $239.81 million. During the same quarter in the prior year, the company posted $0.76 earnings per share. The company’s quarterly revenue was up 68.1% on a year-over-year basis. Analysts expect that Questcor Pharmaceuticals will post $6.89 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Tuesday, July 8th. Investors of record on Tuesday, July 1st will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 1.38%.

QCOR has been the subject of a number of recent research reports. Analysts at Piper Jaffray downgraded shares of Questcor Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday. They now have a $98.00 price target on the stock, up previously from $96.00. Separately, analysts at Oppenheimer reiterated an “outperform” rating on shares of Questcor Pharmaceuticals in a research note on Monday, April 21st. They now have a $86.00 price target on the stock, down previously from $99.00. Finally, analysts at Mizuho cut their price target on shares of Questcor Pharmaceuticals from $93.00 to $92.00 in a research note on Tuesday, April 8th. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Questcor Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $84.20.

Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.